Ellagic acid attenuates bleomycin and cyclophosphamide-induced pulmonary toxicity in Wistar rats

Food and Chemical Toxicology

Volumn 58, Issue , 2013, Pages 210-219

  Saba, ^a   Khan, Somaira ^a   Parvez, Suhel ^a   Chaudhari, Bhushan ^b   Ahmad, Firoz ^a   Anjum, Sameya ^a   Raisuddin, Sheikh ^a  

^a HAMDARD UNIVERSITY   (India)

^b CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

Bleomycin; Bronchoalveolar lavage fluid; Cyclophosphamide; Ellagic acid; Oxidative stress; Pulmonary toxicity

Indexed keywords

ALKALINE PHOSPHATASE; BLEOMYCIN; CARBONYL DERIVATIVE; CATALASE; CYCLOPHOSPHAMIDE; ELLAGIC ACID; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HYDROXYPROLINE; LACTATE DEHYDROGENASE; MYELOPEROXIDASE; NITRIC OXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HISTOPATHOLOGY; LIPID PEROXIDATION; LUNG LAVAGE; LUNG TOXICITY; MALE; NONHUMAN; OXIDATIVE STRESS; PROPHYLAXIS; RAT;

BALF; BLEOMYCIN; BLM; BRONCHOALVEOLAR LAVAGE FLUID; CP; CYCLOPHOSPHAMIDE; EA; ELLAGIC ACID; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE S-TRANSFERASE; GPX; GR; GSH; GST; LIPID PEROXIDATION; LPO; OXIDATIVE STRESS; PULMONARY TOXICITY; REACTIVE OXYGEN SPECIES; REDUCED GLUTATHIONE; ROS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BLEOMYCIN; BRONCHOALVEOLAR LAVAGE FLUID; CYCLOPHOSPHAMIDE; ELLAGIC ACID; LUNG; MALE; RATS; RATS, WISTAR;

EID: 84878127114     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2013.03.046     Document Type: Article

References (95)

1. Abhishek A., Yazdani R., Pearce F., Regan M., Lim K., Hubbard R., Lanyon P. Outcome of systemic sclerosis associated interstitial lung disease treated with intravenous cyclophosphamide. Clin. Rheumatol. 2011, 30:1099-1104.
2. Ayrton A.D., Lewis D.F., Walker R., Ioannides C. Antimutagenicity of ellagic acid towards the food mutagen IQ: investigation into possible mechanisms of action. Food Chem. Toxicol. 1992, 30:289-295.
3. Azambuja E., Fleck J.F., Batista R.G., Menna Barreto S.S. Bleomycin lung toxicity: who are the patients with increased risk. Pulm. Pharmacol. Ther. 2005, 18:363-366.
4. Beauchamp C., Fridovich I. Superoxide dismutase: improved assays and an assay applicable to acrylamide gels. Anal. Biochem. 1971, 44:276-287.
5. Bhatia K., Kaur M., Atif F., Ali M., Rehman H., Rahman S., Raisuddin S. Aqueous extract of Trigonella foenum graecum L. ameliorates additive urotoxicity of buthionine sulfoximine and cyclophosphamide in mice. Food Chem. Toxicol. 2006, 44:1744-1750.
6. Bhatia K., Ahamd F., Rashid H., Raisuddin S. Protective effect of S-allyl cysteine against cyclophosphamide-induced bladder hemorrhagic cystitis in mice. Food Chem. Toxicol. 2008, 46:3368-3374.
7. Boyuk A., Onder A., Kapan M., Gumus M., Firat U., Basarali M.K., Alp H. Ellagic acid ameliorates lung injury after intestinal ischemia-reperfusion. Pharmacogn. Mag. 2011, 7:224-228.
8. Bradley P.P., Priebat D.A., Christensen R.D., Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophill content with an enzyme marker. J. Invest. Dermatol. 1982, 78:206-209.
9. Carlberg I., Mannervik B. Purification and characterization of the flavoenzyme glutathione reductase from rat liver. J. Biol. Chem. 1975, 250:5475-5480.
10. Cerda B., Llorach R., Ceron J.J., Espin J.C., Tomas-Barberan F.A. Evaluation of the bioavailability and metabolism in the rat of punicalagin and antioxidant polyphenol from pomegranate juice. Eur. J. Nutr. 2003, 42:18-28.
11. Cerda B., Espin J.C., Parra S., Martinez P., Tomas-Barberan F.A. The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolized into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora in healthy humans. Eur. J. Nutr. 2004, 43:205-220.
12. Chaudhary N.I., Schnapp A., Park J.E. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am. J. Respir. Crit. Care Med. 2006, 173:769-776.
13. Claiborne A. Catalase activity. Handbook of Methods for Oxygen Radical Research 1985, 283-284. CRC Press, Boca Raton. R.A. Greenwald (Ed.).
14. Dahlen I., Janson C., Bjornsson E., Stalenheim G., Peterson C.G., Venge P. Changes in inflammatory markers following treatment of acute exacerbations of obstructive pulmonary disease. Respir. Med. 2001, 95:891-897.
15. Day B.J. Antioxidants as potential therapeutics for lung fibrosis. Antioxid. Redox Signal. 2008, 10:355-370.
16. Dehler M., Zessin E., Bartsch P., Mairbaurl H. Hypoxia causes permeability oedema in the constant-pressure perfused rat lung. Eur. Respir. J. 2006, 27:600-606.
17. Devipriya N., Sudheer A.R., Srinivasan M., Menon V.P. Effect of ellagic acid, a plant polyphenol, on fibrotic markers (MMPs and TIMPs) during alcohol induced hepatotoxicity. Toxicol. Mech. Methods 2007, 17:349-356.
18. Doi M., Okamoto Y., Yamauchi M., Naitou H., Shinozaki K. Bleomycin induced pulmonary fibrosis after tumor lysis syndrome in a case of advanced yolk sac tumor treated with bleomycin, etoposide and cisplatin (BEP) chemotherapy. Int. J. Clin. Oncol. 2012, 17:528-531.
19. El-Agamy D.S. Nilotinib ameliorates lipopolysaccharide-induced acute lung injury in rats. Toxicol. Appl. Pharmacol. 2011, 253:153-160.
20. El-Sayyad H.I., Ismail M.F., Shalaby F.M., Abou-El-Magd R.F., Gaur R.L., Fernando A., Raj M.H., Ouhtit A. Histopathological effects of cisplatin, doxorubicin and 5-flurouracil (5-FU) on the liver of male albino rats. Int. J. Biol. Sci. 2009, 5:466-473.
21. Espin J.C., Gonzalez-Barrio R., Cerda B., Lopez-Bote C., Rey A.I., Tomas-Barberan F.A. Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans. J. Agric. Food Chem. 2007, 55:10476-10485.
22. Forman H.J., Zhang H., Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol. Aspects Med. 2009, 30:1-12.
23. Gainok J., Daniels R., Golembiowski D., Kindred P., Post L., Strickland R., Garrett N. Investigation of the anti-inflammatory, antinociceptive effect of ellagic acid as measured by digital paw pressure via the Randall selitto meter in male Sprague Dawley rats. AANA. J. 2011, 79:S28-34.
24. Gonzlez-Sarrías A., Larrosa M., Tomas-Barberan F.A., Dolara P., Espin J.C. NF-kappaB-dependent anti-inflammatory activity of urolithins, gut microbiota ellagic acid-derived metabolites, in human colonic fibroblasts. Br. J. Nutr. 2010, 104:503-512.
25. Gou M., Shi H., Guo G., Men K., Zhang J., Zheng L., Li Z., Luo F., Qian Z., Zhao X., Wei Y. Improving anticancer activity and reducing systemic toxicity of doxorubicin by self-assembled polymeric micelles. Nanotechnology 2011, 22:095102.
26. Gurujeyalakshmi G., Wang Y., Giri S.N. Suppression of bleomycin-induced nitric oxide production in mice by taurine and niacin. Nitric Oxide 2000, 4:399-411.
27. Habig W.H., Pabst M.J., Jakoby W.B. Glutathione S-transferase. The first enzymatic step in mercapturic acid formation. J. Biol. Chem. 1974, 249:7130-7139.
28. Hagiwara S., Iwasaka H., Matsumoto S., Noguchi T. Antisense oligonucleotide inhibition of heat shock protein (HSP) 47 improves bleomycin-induced pulmonary fibrosis in rats. Respir. Res. 2007, 15:8-37.
29. Haque R., Bin-Hafeez B., Parvez S., Pandey S., Sayeed I., Ali M., Raisuddin S. Aqueous extract of walnut (Juglans regia L) protects mice against cyclophoshamide induced biochemical toxicity. Hum. Exp. Toxicol. 2003, 22:473-480.
30. Henderson R.F., Benson J.M., Hahn F.F., Hobbs C.H., Jones R.K., Mauderly J.L., McClellan R.O., Pickrell J.A. New approaches for the evaluation of pulmonary toxicity: bronchoalveolar lavage fluid analysis. Fundam. Appl. Toxicol. 1985, 5:451-458.
31. Ishimoto H., Shibata M., Myojin Y., Ito H., Sugimoto Y., Tai A., Hatano T. In vivo anti-inflammatory and antioxidant properties of ellagitannin metabolite urolithin A. Bioorg. Med. Chem. Lett. 2011, 21:5901-5904.
32. Jin C., Zhou D., Lv F. Beneficial effects of early (but not late) intervention of hemeoxygenase-1 on bleomycin-induced pulmonary fibrosis in mice. Respir. Physiol. Neurobiol. 2011, 175:239-246.
33. Jollow D.J., Mitchell J.R., Zampaglione N., Gillete J.R. Bromobenzene induced liver necrosis: protective role of glutathione and evidence for 3,4-bromobenzene oxide as the hepatotoxic intermediate. Pharmacology 1974, 11:151-169.
34. Kalpana C., Rajasekharan K.N., Menon V.P. Modulatory effects of curcumin and curcumin analog on circulatory lipid profiles during nicotine-induced toxicity in Wistar rats. J. Med. Food 2005, 8:246-250.
35. Kalpana C., Sudheer A.R., Rajasekharan K.N., Menon V.P. Comparative effects of curcumin and its synthetic analogue on tissue lipid peroxidation and antioxidant status during nicotine-induced toxicity. Singapore Med. J. 2007, 48:124-130.
36. Kannan M.M., Quine S.D. Ellagic acid inhibits cardiac arrhythmias, hypertrophy and hyderlipidaemia during myocardial infarction in rats. Metabolism 2013, 62:52-61.
37. Kara H., Karatas F., Tug T., Canatan H., Karaoglu A. Protective effect of octreotide on intra-tracheal bleomycin induced oxidative damage in rats. Exp. Toxicol. Pathol. 2010, 62:235-241.
38. Kehrer J.P., Kacew S. Systemically applied chemicals that damage lung tissue. Toxicology 1985, 35:25l-293.
39. Kehrer J.P., Margolin S.B. Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol. Lett. 1997, 90:125-132.
40. Kinnula V.L., Crapo J.D., Raivio K.O. Generation and disposal of reactive oxygen metabolites in the lung. Lab. Invest. 1995, 73:3-19.
41. Kornberg, A., 1955. Lactic dehydrogenase of muscle. In: Colowick, S.P., Kaplan, N.O. (Eds.), Methods Enzymol. 1, 441-443.
42. Landete J.M. Ellagitannins, ellagic acid and their derived metabolites: a review about source, metabolism, functions and health. Food Res. Int. 2011, 44:1150-1160.
43. Larrosa M., Gonzalez-Sarrias A., Yanez-Gascon M.J., Selma M.V., Azorin-Ortuno M., Toti S., Tomas-Barberan F., Dolara P., Espin J.C. Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. J. Nutr. Biochem. 2010, 21:717-725.
44. Lepovire M., Chenais B., Yapo A., Lemaire G., Thelander L., Tenu J.P. Alterations of ribonucleotide reductase activity following induction of nitrite generating pathway in adenocarcinoma cells. J. Biol. Chem. 1990, 265:14143-14149.
45. Levine R.L., Williams J.A., Stadtman E.R., Shacter E. Carbonyl assay for determination of oxidatively modified proteins. Methods Enzymol. 1994, 233:346-357.
46. Li Y.J., Azuma A., Usuki J., Abe S., Matsuda K., Sunazuka T., Shimizu T., Hirata Y., Inagaki H., Kawada T., Takahashi S., Kudoh S., Omura S. EM703 improves bleomycin induced pulmonary fibrosis in mice by the inhibition of TGF-beta signaling in lung fibroblasts. Respir. Res. 2006, 27:7-16.
47. Lin M.C., Yin M.C. Preventive effects of ellagic acid against doxorubicin-induced cardio-toxicity in mice. Cardiovasc. Toxicol 2013, 10.1007/s12012-013-9197-Z.
48. Liu R., Ahmed K.M., Nantajit D., Rosenthal F.S., Hai C.X., Li J.J. Therapeutic effects of α-lipoic acid on bleomycin-induced pulmonary fibrosis in rats. Int. J. Mol. Med. 2007, 19:865-873.
49. Liu F., Li X.L., Lin T., He D.W., Wei G.H., Liu J.H., Li L.S. The cyclophosphamide metabolite, acrolein, induces cytoskeleton changes and oxidative stress in sertoli cells. Mol. Biol. Rep. 2012, 39:493-500.
50. 1 in the Salmonella microsuspension assay. Mutat. Res. 1998, 398:183-187.
51. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
52. MacNee W., Rahman I. Oxidants/antioxidants in idiopathic pulmonary fibrosis. Thorax 1995, 50:S53-S58.
53. Mayo J.C., Sainz R.M., Antoli I., Herrera F., Martin V., Rodriguez C. Melatonin regulation of antioxidant enzyme gene expression. Cell. Mol. Life Sci. 2002, 59:706-713.
54. Mihara M., Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal. Biochem. 1978, 86:271-278.
55. Mohandas J., Marshall J.J., Duggins G.G., Horvath J.S., Tiller D. Differential distribution of glutathione and glutathione related enzymes in rabbit kidneys. Possible implications in analgesic nephropathy. Biochem. Pharmacol. 1984, 33:1801-1807.
56. Niitsu N., Okamoto M., Aoki S., Okumura H., Yoshino T., Miura I., Hirano M. Multicenter phase II study of the CyclOBEAP (CHOP-like+etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma. Ann. Hematol. 2006, 85:374-380.
57. Pari L., Sivasankari R. Effect of ellagic acid on cyclosporine A-induced oxidative damage in the liver of rats. Fundam. Clin. Pharmacol. 2008, 22:395-401.
58. Patel J.M., Block E.R., Hood C.I. Biochemical indices of cyclophosphamide induced lung toxicity. Toxicol. Appl. Pharmacol. 1984, 76:128-138.
59. Pini A., Shemesh R., Samuel C.S., Bathgate R.A., Zauberman A., Hermesh C., Wool A., Bani D., Rotman G. Prevention of bleomycin induced pulmonary fibrosis by a novel antifibrotic Peptide with relaxin like activity. J. Pharm. Exp. Ther. 2010, 335:589-599.
60. Plasse T.F., Ohnuma T., Brooks S., Saponaro E., Holland J.F., Biller H. Bleomycin infusion followed by cyclophosphamide, methotrexate, and 5-fluorouracil in advanced squamous carcinoma of the head and neck. Cancer 1984, 53:841-843.
61. Priyadarsini K.I., Khopde S.M., Kumar S.S., Mohan H. Free radical studies of ellagic acid, a natural phenolic antioxidant. J. Agric. Food Chem. 2002, 50:2200-2206.
62. Punithavathi D., Venkatesan N., Babu M. Curcumin inhibition of bleomycin induced pulmonary fibrosis in rats. Br. J. Pharmacol. 2000, 131:169-172.
63. Punithavathi D., Venkatesan N., Babu M. Protective effects of curcumin against amiodarone induced pulmonary fibrosis in rats. Br. J. Pharmacol. 2003, 139:1342-1350.
64. Quinlan T., Spivack S., Mossman B.T. Regulation of antioxidant enzymes in lung after oxidant injury. Environ. Health Perspect. 1994, 2:79-87.
65. Raghavendran K., Davidson B.A., Hutson A.D., Helinski J.D., Nodzo S.R., Notter R.H., Knight P.R. Predictive modeling and inflammatory biomarkers in rats with lung contusion and gastric aspiration. J. Trauma 2009, 67:1182-1190.
66. Rehman M.U., Tahir M., Ali F., Qamar W., Lateef A., Khan R., Quaiyoom A., Oday O.H., Sultana S. Cyclophoshamide induced nephrotoxicity, genotoxicity, and damage in kidney genomic DNA of Swiss albino mice: the protective effect of ellagic acid. Mol. Cell. Biochem. 2012, 365:119-127.
67. Rhoden C.R., Lawrence J., Godleski J.J., Gonzalez Flecha B. N-acetylcysteine prevents lung inflammation after short term inhalation exposure to concentrated ambient particles. Toxicol. Sci. 2004, 79:296-303.
68. Ricciardolo F.L., Sterk P.J., Gaston B., Folkerts G. Nitric oxide in health and disease of the respiratory system. Physiol. Rev. 2004, 84:731-765.
69. Rogerio A.P., Fontanari C., Melo M.C., Ambrosio S.R., De Souza G.E., Pereira P.S., Franca S.C., Da Costa F.B., Albuquerque D.A., Faccioli L.H. Anti inflammatory, analgesic and antiedematous effects of Lafoensia pacari extract and ellagic acid. J. Pharm. Pharmacol. 2006, 58:1265-1273.
70. Sangaletti S., Tripodo C., Cappetti B., Casalini P., Chiodoni C., Piconese S., Santangelo A., Parenza M., Arioli I., Miotti S., Colombo M.P. SPARC oppositely regulates inflammation and fibrosis in bleomycin induced lung damage. Am. J. Pathol. 2011, 179:3000-3010.
71. Sayed-Ahmed M.M., Eissa M.A., Kenawy S.A., Mostafa N., Calvani M., Osman A.M. Progression of cisplatin induced nephrotoxicity in carnitine depleted rat model. Chemotherapy 2004, 50:162-170.
72. Schrier D.J., Phan S.H. Modulation of bleomycin induced pulmonary fibrosis in the BALB/c mouse by cyclophosphamide-sensitive T cells. Am. J. Pathol. 1984, 116:270-278.
73. Seeram N.P., Lee R., Heber D. Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin. Chim. Acta 2004, 348:63-68.
74. Sen C.K. Oxygen toxicity and antioxidants: state of the art. Indian J. Physiol. Pharmacol. 1995, 39:177-196.
75. Serrano-Mollar A., Closa D., Prats N., Blesa S., Martinez- Losa M., Cortijo J., Estrela J.M., Morcillo E.J., Bulbena O. In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats. Br. J. Pharmacol. 2003, 138:1037-1048.
76. Sisson T.H., Mendez M., Choi K., Subbotina N., Courey A., Cunningham A., Dave A., Engelhardt J.F., Liu X., White E.S., Thannickal V.J., Moore B.B., Christensen P.J., Simon R.H. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2010, 181:254-263.
77. Shang Y., Xu S.P., Wu Y., Jiang Y.X., Wu Z.Y., Yuan S.Y., Yao S.L. Melatonin reduces acute lung injury in endotoxemic rats. Chin. Med. J. Engl. 2009, 122:1388-1393.
78. Smith R.E., Strieter R.M., Phan S.H., Lukacs N.W., Huffnagle G.B., Wilke C.A., Burdick M.D., Lincoln P., Evanoff H., Kunkel S.L. Production and function of murine macrophage inflammatory protein-1a in bleomycin induced lung injury. J. Immunol. 1994, 153:4704-4712.
79. Soliman K.F., Mazzio E.A. In vitro attenuation of nitric oxide production in C6 astrocyte cell culture by various dietary compounds. Proc. Soc. Exp. Biol. Med. 1998, 218:390-397.
80. Sriram N., Kalayarasan S., Sudhandiran G. Epigallocatechin-3-gallate exhibits anti-fibrotic effect by attenuating bleomycin-induced glycoconjugates, lysosomal hydrolases and ultrastructural changes in rat model pulmonary fibrosis. Chem. Biol. Interact. 2009, 180:271-280.
81. Sulkowska M., Sulkowski S. The effect of pentoxifylline on ultrastructural picture of type II alveolar epithelial cells and generation of reactive oxygen species during cyclophoshamide induced lung injury. J. Submicrosc. Cytol. Pathol. 1997, 29:487-496.
82. Sulkowska M., Sulkowski S. Alveolar cells in cyclophosphamide induced lung injury. An ultrastructural analysis of type II alveolar epithelial cells in situ. Histol. Histopathol. 1998, 13:13-20.
83. Sun Y., Zhang J., Yan Y., Chi M., Chen W., Sun P., Qin S. The protective effect of C-phycocyanin on paraquat-induced acute lung injury in rats. Environ. Toxicol. Pharmacol. 2011, 32:168-174.
84. Takenaka T., Mikuni C., Miura A., Sasaki T., Suzuki H., Hotta T., Hirano M., Fukuhara S., Sugiyama H., Nasu K., Dohi H., Kozuru M., Tomonaga M., Tajima K., Niimi M., Fukuda H., Mukai K., Shimoyama M. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group. Jpn. J. Clin. Oncol. 2000, 30:146-152.
85. Teixeira K.C., Soares F.S., Rocha L.G., Silveira P.C., Silva L.A., Valenca S.S., Pizzol F.Dal, Streck E.L., Pinho R.A. Attenuation of bleomycin-induced lung injury and oxidative stress by N-acetylcysteine plus deferoxamine. Pulm. Pharmacol. Ther. 2008, 21:309-316.
86. Thresiamma K.C., George J., Kuttan R. Protective effect of curcumin, ellagic acid and bixin on radiation induced toxicity. Indian J. Exp. Biol. 1996, 34:845-847.
87. Townsend D.M., Tew K.D., Tapiero H. The importance of glutathione in human disease. Biomed. Pharmacother. 2003, 57:145-155.
88. Uchida K., Shiraishi M., Naito Y., Torii N., Nakamura Y., Osawa T. Activation of stress signaling pathways by the end product of lipid peroxidation. J. Biol. Chem. 1999, 274:2234-2242.
89. Unemori E.N., Pickford L.B., Salles A.L., Piercy C.E., Grove B.H., Erikson M.E., Amento E.P. Relaxin induces an extracellular matrix degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J. Clin. Invest. 1996, 98:2739-2745.
90. Wei X.J., Hu T.J., Chen J.R., Wei Y.Y. Inhibitory effect of carboxymethylpachymaran on cyclophosphamide-induced oxidative stress in mice. Int. J. Biol. Macromol. 2011, 49:801-805.
91. Wenk M.R., Fernandis A.Z. Manuals in biomedical research. A Manual for Biochemistry Protocols 2007, vol. 3. World Scientific Publishing 554 Co. Pte. Ltd., Singapore, p. 90.
92. Yang H., Ganguly A., Cabral F. Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting drugs. J. Biol. Chem. 2010, 285:32242-32250.
93. Yu Y.M., Chang W.C., Wu C.H., Chiang S.Y. Reduction of oxidative stress and apoptosis in hyperlipidemic rabbits by ellagic acid. J. Nutr. Biochem. 2005, 16:675-681.
94. Yuce A., Atessahin A., Ceribasi A.O. Amelioration of cyclosporine A-induced renal, hepatic and cardiac damages by ellagic acid in rats. Basic Clin. Pharmacol. Toxicol. 2008, 103:186-191.
95. Zhang B., Liu Z.Y., Li Y.Y., Luo Y., Liu M.L., Dong H.Y., Wang Y.X., Liu Y., Zhao P.T., Jin F.G., Li Z.C. Anti inflammatory effects of matrine in LPS-induced acute lung injury in mice. Eur. J. Pharm. Sci. 2011, 44:573-579.